{"commentary":{"count":37,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":19,"podcast":17,"x_thread":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05173987\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT05173987","nct_id":"NCT05173987","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05173987. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Participants receive pembrolizumab 400 mg via IV infusion on Day 1 of each 6-week cycle (Q6W) for up to 18 cycles (up to approximately 2 years).","label":"Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Participants receive a combination of paclitaxel 175 mg/m\\^2 on Day 1 of each 3-week cycle (Q3W) and carboplatin AUC 5 or 6 on Day 1 Q3W for 6 cycles (up to approximately 4 months). Participants who experience a severe hypersensitivity reaction to paclitaxel or an adverse event (AE) requiring discontinuation of paclitaxel may receive docetaxel 75 mg/m\\^2 in place of paclitaxel on Day 1 Q3W after Sponsor consultation. Participants who experience a severe hypersensitivity reaction to carboplatin or an AE requiring discontinuation of carboplatin may receive cisplatin 75 mg/m\\^2 in place of carboplatin on Day 1 Q3W after Sponsor consultation.","label":"Carboplatin+paclitaxel","type":"ACTIVE_COMPARATOR"}],"collaborators":["European Network of Gynaecological Oncological Trial Groups (ENGOT)","GOG Foundation"],"completion_date":{"date":"2027-05-27","type":"ESTIMATED"},"conditions":["Endometrial Neoplasms"],"enrollment":{"count":280,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"pembrolizumab","type":"BIOLOGICAL"},{"name":"carboplatin","type":"DRUG"},{"name":"paclitaxel","type":"DRUG"},{"name":"docetaxel","type":"DRUG"},{"name":"cisplatin","type":"DRUG"}],"last_update":"2026-05-05","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-05-27","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to approximately 45 months"},{"measure":"Overall Survival","timeFrame":"Up to approximately 59 months"}],"references":[{"citation":"Secord AA, Powell MA, McAlpine J. Molecular Characterization and Clinical Implications of Endometrial Cancer. Obstet Gynecol. 2025 Nov 1;146(5):660-671. doi: 10.1097/AOG.0000000000006080. Epub 2025 Sep 18.","pmid":"40966692","type":"DERIVED"}],"start_date":{"date":"2022-02-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)","url":"https://clinicaltrials.gov/study/NCT05173987"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05173987"}